LENZ Expands VIZZ Access with Telehealth Prescribing Option

What happened

LENZ Therapeutics launched a telehealth prescribing option for VIZZ (aceclidine) for presbyopia, supplementing existing access through eye care professionals. This move reduces prescribing friction and could accelerate patient conversion post the January 2026 DTC campaign. While the telehealth channel is a low-cost way to expand reach, it does not directly address the retinal tear/detachment label concern that weighs on prescriber adoption and persistence. The Q4 2025 launch baseline showed $1.6M net revenue and >20,000 prescriptions, and this telehealth option may help lift Q1–Q2 2026 numbers, but the fundamental question remains whether repeat prescribing can sustain a fixed-cost commercial base.

Implication

Telehealth expands the addressable patient pool but does not alter the core investment thesis: VIZZ needs durable repeat prescribing to justify the 88-territory sales force and DTC spend. This news marginally improves the probability of the base case (50%, $14) by lowering access friction, but the bear case (30%, $7) from safety concerns remains intact. Only material sequential revenue growth or label clarification will shift the long-term outlook.

Thesis delta

The telehealth launch modestly increases the likelihood of near-term demand acceleration by reducing prescription friction, but it does not alter the central bear-case risk from retinal safety headlines or the need for repeat prescribing proof. The balance shifts slightly toward the base scenario from the bear scenario, but not enough to change the overall rating or conviction.